Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Axsome Therapeutics (NASDAQ:AXSM) and Moderna (NASDAQ:MRNA) requires balancing rapid commercial expansion against the potential of a massive, multi-use technology platform during a period of industrial shift.

Axsome focuses on treating complex central nervous system conditions with a growing portfolio of approved drugs. Moderna is leveraging its mRNA technology to move beyond the pandemic, targeting various viruses and cancers. Both companies are navigating the high-risk, high-reward landscape of drug development and commercialization.

The case for Axsome Therapeutics

Axsome Therapeutics operates as a biopharmaceutical company dedicated to central nervous system (CNS) conditions. Its current commercial lineup includes AUVELITY for depression, SUNOSI for narcolepsy, and SYMBRAVO. The company has rapidly scaled its presence, reaching nearly 925 full-time employees by early 2026. While it manages its own commercial efforts in the United States, it utilizes strategic partnerships, such as its licensing deal with Pharmanovia, to reach patients in Europe, the Middle East, and North Africa.

In FY 2025, revenue reached nearly $638.5 million, marking a significant increase of approximately 65.5% compared to the prior year. This performance continues a strong multi-year trend, as the company had generated roughly $270.6 million in FY 2023. Axsome reported a net loss of close to $183.2 million for the year, resulting in a net margin of negative 28.7%. These results highlight the costs associated with scaling biotech stocks that are moving from the laboratory into the mainstream medical market.

As of its December 2025 balance sheet, the debt-to-equity ratio was 2.7x, indicating that total liabilities are nearly 2.7 times the value of shareholder equity. The current ratio, which measures a company's ability to cover its short-term debts with its short-term assets, was approximately 1.6x. Free cash flow, or the cash left over after paying for operations and capital expenditures, was negative $93.9 million in FY 2025. This negative cash flow reflects the company's ongoing investment in marketing and clinical development for its expanding pipeline.

The case for Moderna

Moderna has established itself as a leader in mRNA technology, moving beyond its initial success in COVID-19 prevention. Its current product portfolio includes Spikevax, mNEXSPIKE, and the RSV vaccine mRESVIA. The company is actively shifting its focus to oncology and other respiratory viruses, maintaining a high-profile collaboration with Merck (NYSE:MRK) for cancer therapies. By the end of 2025, Moderna expected to streamline its workforce to fewer than 5,000 employees as it optimizes its operations for a post-pandemic market.

In FY 2025, revenue reached nearly $1.9 billion, which was a decrease of approximately 39.2% from the previous fiscal year. This decline is largely attributed to the expected reduction in demand for COVID-19 vaccines globally. The company reported a net loss of close to $2.8 billion for the period, and its net margin was negative 145.2%. These figures show the heavy financial weight of maintaining a massive research and development engine while transitioning between major product cycles.

According to its December 2025 balance sheet, the debt-to-equity ratio was approximately 0.2x, suggesting a low level of debt relative to equity. The current ratio was roughly 3.3x, showing a strong position to meet short-term financial obligations. Free cash flow for FY 2025 was negative $2.1 billion, reflecting the significant capital required to pivot the mRNA platform toward new indications. Despite the current losses, the strong liquidity position provides a buffer for its multi-year development plans.

Risk profile comparison

Axsome Therapeutics faces risks related to its ongoing operating losses and the potential need for additional capital to fund its expansion. The business is heavily reliant on the commercial success of a few key products, namely AUVELITY and SUNOSI. Furthermore, the company is involved in patent litigation with generic manufacturers such as Apotex, which could impact its long-term revenue protection. Regulatory hurdles and price pressures also remain constant factors for companies in the CNS market.

Moderna faces intense competition in the vaccine and oncology sectors from established giants like Pfizer (NYSE:PFE), GSK (NYSE:GSK), and Sanofi (NASDAQ:SNY). Its financial performance has been impacted by large litigation settlement payments, and it continues to defend its intellectual property in high-stakes court cases. Additionally, the complexity of mRNA manufacturing and cold-chain logistics adds operational risk. Any changes in FDA advisory committee recommendations could also disrupt the launch of its future pipeline candidates.

Valuation comparison

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with Moderna, though Axsome makes this closer than it might initially seem. Axsome has built a commercial drug portfolio faster than most small biotechs manage, and a new FDA approval targeting a common and difficult-to-treat symptom in Alzheimer's patients adds a promising indication. Although the company believes it has enough cash to reach profitability without raising more money, there is not much margin for error from here, but the commercial momentum is real.

Moderna is playing in an entirely different league. Its mRNA flu vaccine just received a unanimous positive recommendation from the FDA's advisory committee, and the cancer therapy pipeline has candidates that could reshape oncology. But the bigger story is the platform itself: mRNA technology works like a universal medicine-making engine that can be retooled for almost any disease by simply changing the genetic instructions it delivers. COVID proved the technology works at scale, and Moderna keeps pointing that engine at new targets.

For investors willing to be patient, Moderna's long-term upside is simply larger.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics, Merck, Moderna, and Pfizer. The Motley Fool recommends GSK. The Motley Fool has a disclosure policy.